Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue was ¥13 million (¥118 million in the same period of the previous year), while selling, general and administrative expenses were ¥907 million (¥860 million in the same period of the previous year). Grant income of ¥82 million under Australia's research and development tax incentive scheme was recorded as non-operating income. Losses are incurred before the related earnings are generated due to long-term upfront investment in pharmaceutical research and development.
The filing includes a description of significant events and other matters related to the going concern assumption. Although operating losses have continued, the Company believes that it has secured funding for research and development and that no material uncertainty exists.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | 13 Millions of yen (YoY -88.8%) |
| Operating profit | -896 Millions of yen |
| Ordinary income | -822 Millions of yen |
| Profit attributable to owners of the parent | -824 Millions of yen |
| Net income per share | -¥13.30 |
| Equity ratio | End of the current fiscal period 91.1 / End of previous period 92.9 |
| Total assets | 1,945 Millions of yen |
| Net assets | 1,827 Millions of yen |
| Full-year earnings forecast | Net Sales 385 Millions of yen (YoY +198.9%) / Operating profit -1,206 Millions of yen / Ordinary income -1,197 Millions of yen / Profit attributable to owners of the parent -1,202 Millions of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen |
| Depreciation and amortization | 6,604 Thousands of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights 9,979 Thousands of yen / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | The filing includes a description of significant events and other matters related to the going concern assumption. Although operating losses have continued, the Company believes that it has secured funding for research and development and that no material uncertainty exists. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | No material changes (no newly included or excluded companies disclosed) |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | No (対象者：None) |
| Issued Shares at Period-End | 70,007,600 shares |
| Treasury Shares at Period-End | 2 shares |
| Factors Behind Changes in Business Performance | Revenue was ¥13 million (¥118 million in the same period of the previous year), while selling, general and administrative expenses were ¥907 million (¥860 million in the same period of the previous year). Grant income of ¥82 million under Australia's research and development tax incentive scheme was recorded as non-operating income. Losses are incurred before the related earnings are generated due to long-term upfront investment in pharmaceutical research and development. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explains that pharmaceutical research and development requires substantial long-term upfront investment and that, as a drug discovery venture, it is pursuing development activities, meaning that losses are incurred before the related earnings are generated. Selling, general and administrative expenses also increased from ¥860 million in the same period of the previous year to ¥907 million.